Scientists in China are reporting discovery of two proteins present in the blood, of people with colon cancer that may serve as the potential biomarkers for accurately predicting whether the disease will spread. Their study is in ACS’ Journal of Proteome Research, a monthly publication.

Abbott (NYSE: ABT) announced it has received CE Marking (Conformite Europeene) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non-invasive DNA assay that detects the methylated form of Septin 9, a gene linked to colorectal cancer, in blood specimens. The product is not available for sale in [...]

A new study examines the occurrence of interval colorectal cancer despite regular colonoscopy and highlights the importance of close follow-up for patients who have a history of advanced adenomas, which are precancerous polyps. Researchers studied the rate of interval colorectal cancer in patients participating in the Polyp Prevention Trial Continued Follow-up Study and found that [...]

Compugen Ltd. (NASDAQ: CGEN) announced the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors. CGEN-671 is a membrane splice variant of CD55, a known drug target for gastric cancer for which monoclonal antibody (mAb) therapeutics are in clinical development by others. The potential application of CGEN-671 as a drug [...]

People carrying the germ-line MSH6 mutation are at high risk by age 80 years for colorectal and endometrial cancers and any cancer associated with Lynch syndrome, according to a new study published online December 22 in the Journal of the National Cancer Institute.